cutting-edge AI technologies
To be a global leader integrating biopharma and AI
To build a healthier world and to make innovative medicines accessible
Integrating tools and experience of computational chemistry, medicinal chemistry and biology, Galixir leverages cutting-edge AI algorithms to resolve problems in preclinical development of small molecule drugs and find candidate molecules with high potency, good druggability and novel structures.
Galixir is collaborating with MNCs, leading domestic pharmaceutical companies, biotech companies on developing pipelines on therapeutic areas including central nervous system diseases, autoimmune diseases, tumors, respiratory diseases. We have made good progress in both inhibitor development and agonist development. By greatly lowering the cost and time of preclinical drug discovery, Galixir makes it possible to develop multiple drug discovery pipelines concurrently and optimize the overall strategic layout.
are from worldwide top-tier universities, first-rate Internet companies and renowned pharmaceutical enterprises
Galixir team members have rich experience in leading drug discovery projects to IND and FDA approval, and machine learning application experience in top-tier Internet companies including Google, Apple and Microsoft. Besides, Galixir has already published nearly 20 papers in top journals and conference proceedings, covering subjects including molecular generation, property prediction and virtual screening and so forth. And our models have kept the world performance record.
Galixir works together with domestic and oversea universities and research institutions including Georgia Institute of Technology, Massachusetts Institute of Technology, University of Pennsylvania, Google Brain of Google AI, Mila, Guangzhou Institutes of Biomedicine and Health of Chinese Academy of Science, Institute of Microbiology of Chinese Academy of Science, Shanghai Jiao Tong University, Zhejiang University and Sun Yat-sen University.